Everus Construction Group, Inc.
ECG
$150.76
+3.88%
Everus Construction Group, Inc. is a U.S.-based construction solutions provider offering specialty contracting services across two primary segments: Electrical & Mechanical (E&M) and Transmission & Distribution (T&D). The company operates as a significant player in the engineering and construction industry, primarily serving public and private sector clients, with its E&M segment generating the majority of revenue. The current investor narrative is heavily focused on the company's explosive growth trajectory and recent public listing, as evidenced by its dramatic stock price appreciation and strong quarterly revenue growth, positioning it as a high-growth story within the industrials sector.…
ECG
Everus Construction Group, Inc.
$150.76
Investment Opinion: Should I buy ECG Today?
Rating: Hold. The core thesis is that ECG's exceptional fundamental growth is compelling but largely priced in at current levels, creating asymmetric risk if execution falters.
Supporting Evidence: The stock trades at a forward PE of 32.07x, a significant premium to both its trailing PE of 21.65x and typical industrial multiples. While revenue growth of 33.15% YoY and net margin expansion to 5.47% are strong, the PEG ratio of 0.54 suggests growth may be undervalued relative to the PE. However, with only one analyst providing estimates and no consensus target price, there's limited institutional validation for further multiple expansion. The stock's 155.91% yearly gain suggests much good news is already reflected.
Risks & Conditions: The two biggest risks are growth deceleration below 25% and multiple compression from the current 32x forward PE. This Hold would upgrade to Buy if the forward PE compresses below 25x while growth remains above 30%, or if a broader analyst consensus emerges with targets implying >20% upside. It would downgrade to Sell if quarterly revenue growth decelerates below 15% or net margins contract sequentially. Relative to its own history and growth profile, the stock appears fairly valued to slightly overvalued, trading near the upper end of its historical PE range (24.31x peak) while expecting accelerated future earnings.
Sign up to view all
ECG 12-Month Price Forecast
ECG presents a classic growth-at-a-reasonable-price dilemma. The fundamentals are undeniably strong with 33% revenue growth and 32% ROE, but the 32x forward PE already prices in perfection. The neutral stance reflects that the risk/reward appears balanced at current levels. The stock likely consolidates in a range as it digests its massive 156% yearly gain. Key to watch is whether Q1 2026 earnings (likely May 2026) show accelerating or decelerating growth trends. The stance would upgrade to bullish on a pullback to $130-$140 where growth would be more compellingly valued, or downgrade to bearish if revenue growth decelerates below 25%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Everus Construction Group, Inc.'s 12-month outlook, with a consensus price target around $195.99 and implied upside of +30.0% versus the current price.
Average Target
$195.99
1 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
1
covering this stock
Price Range
$121 - $196
Analyst target range
Analyst coverage is limited, with data indicating only one firm providing estimates, resulting in insufficient consensus for a meaningful average target price and implied upside/downside calculation. The institutional ratings from several firms show a mixed but generally positive sentiment, with recent actions including 'Buy' ratings from Freedom Broker and Stifel and 'Neutral' ratings from DA Davidson, but no specific price targets are provided in the available data. The lack of a broad analyst consensus and specific target range signals this is a company with limited institutional coverage, which is typical for a recently listed firm (IPO in October 2024). This environment can lead to higher volatility and less efficient price discovery, as the stock's narrative is still being established. The presence of both bullish and neutral ratings from reputable firms indicates ongoing debate about the sustainability of its growth and the justification for its current valuation premium.
Bulls vs Bears: ECG Investment Factors
The bull case for ECG is compelling, grounded in exceptional 33% revenue growth, expanding profitability, and a fortress balance sheet. However, the bear case highlights significant risks from its premium valuation, limited analyst coverage, and technical overextension after a 156% yearly rally. Currently, the bull side has stronger evidence due to the concrete, accelerating fundamental performance. The single most important tension in the investment debate is whether ECG can sustain its current 33%+ revenue growth rate to justify its forward PE of 32x. If growth persists, the stock could re-rate higher; if it decelerates even moderately, the elevated multiple creates substantial downside risk.
Bullish
- Explosive Revenue Growth: Q4 2025 revenue grew 33.15% YoY to $1.01B, accelerating from sequential growth throughout the year. This demonstrates strong demand and execution in its core Electrical & Mechanical segment, which generated $407.97M in the latest period.
- Strong Profitability & Margin Expansion: Net income reached $55.28M in Q4 with a net margin of 5.47%, up from 4.44% in Q1 2025. The company's Return on Equity is exceptionally high at 32.04%, indicating highly efficient use of shareholder capital.
- Robust Balance Sheet & Cash Flow: The company has minimal leverage with a debt-to-equity ratio of 0.17 and strong liquidity with a current ratio of 1.76. It generated $90.01M in trailing free cash flow, providing internal funding for continued growth.
- Powerful Technical Momentum: The stock is up 155.91% over the past year and 49.03% over the past three months, significantly outperforming the S&P 500. It trades at 91% of its 52-week high, indicating sustained bullish momentum.
Bearish
- Premium Valuation with High Expectations: The forward PE of 32.07x is significantly higher than the trailing PE of 21.65x, indicating the market is pricing in nearly 50% EPS growth. This leaves little room for error and creates vulnerability to multiple compression if growth decelerates.
- Limited Analyst Coverage & Price Discovery: Only one analyst provides estimates, resulting in no meaningful consensus target price. Mixed institutional ratings (Buy and Neutral) with limited coverage suggest the investment narrative is still being established, leading to potential volatility.
- Potential Technical Overextension: Trading at $156.72, the stock sits 91% of the way from its 52-week low to its high of $171.58. Recent daily declines of -4.42% and a high short ratio of 3.65 suggest the parabolic move may be exhausted, increasing near-term correction risk.
- Sector-Leading Multiples: The trailing PE of 21.65x and PS ratio of 1.17 trade at a premium to typical construction sector multiples. While justified by growth, this premium makes the stock sensitive to sector rotation away from growth and toward value within industrials.
ECG Technical Analysis
The stock is in a powerful, sustained uptrend, evidenced by a staggering 155.91% gain over the past year. Currently trading at $156.72, it sits near the top of its 52-week range, approximately 91% of the way from its low of $55.31 to its high of $171.577, indicating strong momentum but also potential overextension. Recent momentum remains exceptionally strong, with the stock up 21.89% over the past month and 49.03% over the past three months, significantly outpacing the S&P 500's gains of 5.6% and 8.42%, respectively, over the same periods, confirming the acceleration of the bullish trend. Key technical levels are clearly defined, with immediate support at the 52-week low of $55.31 and formidable resistance at the recent high of $171.577. A decisive breakout above $171.58 would signal a continuation of the parabolic move, while a breakdown below the recent consolidation low near $110 could indicate a significant correction. The stock exhibits high volatility, with a short ratio of 3.65 suggesting elevated bearish sentiment and potential for sharp moves, which aligns with the price's dramatic ascent and recent pullbacks like the -4.42% daily decline observed.
Beta
—
—
Max Drawdown
-20.3%
Largest decline past year
52-Week Range
$57-$172
Price range past year
Annual Return
+161.8%
Cumulative gain past year
| Period | ECG Return | S&P 500 |
|---|---|---|
| 1m | +1.1% | +5.4% |
| 3m | +26.7% | +10.9% |
| 6m | +59.6% | +11.0% |
| 1y | +161.8% | +28.1% |
| ytd | +69.1% | +11.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ECG Fundamental Analysis
Revenue growth is exceptionally strong and accelerating. The most recent quarterly revenue for Q4 2025 was $1.01 billion, representing a 33.15% year-over-year increase. This follows a multi-quarter trend of robust growth, with sequential quarterly revenues rising from $826.6M in Q1 to $1.01B in Q4 of 2025. The Electrical & Mechanical segment, with $407.97 million in the latest period, is the primary growth driver, significantly larger than the Transmission & Distribution segment's $113.28 million. The company is profitable with expanding margins. Net income for Q4 2025 was $55.28 million, translating to a net margin of 5.47%. Gross margin for the quarter was 11.62%, while the operating margin stood at 6.81%. Profitability has improved sequentially from Q1 2025, where net income was $36.67 million with a net margin of 4.44%, indicating margin expansion through the year. The trailing twelve-month free cash flow of $90.01 million supports this profitability. The balance sheet is healthy with low leverage and strong liquidity. The debt-to-equity ratio is a conservative 0.17, indicating minimal financial risk. The current ratio is a robust 1.76, demonstrating ample short-term liquidity. Return on Equity (ROE) is a very strong 32.04%, highlighting efficient use of shareholder capital. The company generated $90.01 million in trailing free cash flow, providing internal funding for growth and reducing reliance on external financing.
Quarterly Revenue
$1.0B
2025-12
Revenue YoY Growth
+0.33%
YoY Comparison
Gross Margin
+0.11%
Latest Quarter
Free Cash Flow
$90009000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ECG Overvalued?
Given a positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE is 21.65x, while the forward PE is significantly higher at 32.07x. This substantial gap indicates the market is pricing in strong future earnings growth, with forward estimates of $7.26 EPS implying a nearly 50% increase from the trailing EPS base. Compared to industry averages, the stock trades at a premium. Its trailing PE of 21.65x and Price-to-Sales (PS) ratio of 1.17 are elevated for the construction sector, which typically features lower multiples. The premium is likely justified by the company's superior growth profile, with a 33.15% YoY revenue increase and a Return on Equity of 32.04% far exceeding typical industrial company metrics, supporting a growth-stock valuation. Historically, the current valuation is near the upper end of its own range. The trailing PE of 21.65x is above the levels seen in early 2025 (e.g., 12.91x in Q1 2025) but below the peak of 24.31x at the end of 2024. This positioning suggests the market has already priced in much of the recent operational improvement and growth acceleration, leaving less room for multiple expansion and increasing reliance on continued execution to meet elevated expectations.
PE
21.6x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 13x~24x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: ECG's primary financial risk is valuation dependency on continued hyper-growth. With a forward PE of 32.07x implying nearly 50% EPS growth, any deceleration in its 33.15% revenue growth trajectory could trigger significant multiple compression. While the balance sheet is strong with 0.17 debt-to-equity, operational risks include revenue concentration in the Electrical & Mechanical segment, which represented the majority of the $1.01B quarterly revenue. Margin pressure is a concern despite recent expansion, as gross margin of 11.62% remains relatively thin for a premium-valued company.
Market & Competitive Risks: The stock trades at a clear premium to its sector, with a trailing PE of 21.65x versus typically lower industrial multiples. This creates valuation compression risk if investor sentiment shifts from growth to value within industrials. The high short ratio of 3.65 indicates elevated bearish sentiment that could fuel sharp declines on any negative news. As a recently listed company (IPO October 2024), ECG faces competitive risks from established players and may experience less efficient price discovery due to limited analyst coverage, increasing volatility.
Worst-Case Scenario: The worst-case scenario involves a simultaneous growth deceleration and multiple compression. If quarterly revenue growth slows to 15-20% (from 33%), and the forward PE contracts to 20x (from 32x), the stock could decline sharply. This could be triggered by a competitive loss, execution misstep, or broader economic slowdown affecting construction spending. Realistic downside could reach the 52-week low of $55.31, representing a -65% decline from the current $156.72. A more probable adverse scenario might see a pullback to the $110 support level observed in March 2026, representing a -30% decline, if the company misses elevated growth expectations.
FAQ
The primary risk is valuation compression if growth decelerates, given the 32x forward PE. Financial risk includes dependence on the Electrical & Mechanical segment for majority revenue. Market risk involves the high short ratio of 3.65 increasing volatility and potential for sharp declines. Competitive risk stems from operating in the fragmented construction sector where pricing pressure could erode thin 11.6% gross margins. Finally, limited analyst coverage creates information asymmetry and less efficient price discovery, exacerbating all other risks.
The 12-month forecast presents three scenarios with associated probabilities. The base case (55% probability) sees the stock trading between $130-$160 as growth meets high expectations but doesn't accelerate further. The bull case (25% probability) targets $171-$200 if growth accelerates and multiple expansion occurs. The bear case (20% probability) warns of a decline to $55-$110 if growth decelerates sharply. The most likely outcome is the base case, assuming ECG maintains but doesn't exceed its current growth trajectory. The key assumption is that quarterly revenue growth remains above 25%.
ECG trades at a premium valuation that appears fairly valued relative to its growth, but overvalued if growth decelerates. The forward PE of 32.07x is high for the construction sector but supported by 33% revenue growth and a PEG ratio of 0.54. Compared to its own history, the trailing PE of 21.65x is near the upper end of its range (peak 24.31x). The valuation implies the market expects sustained high growth and margin expansion. If those expectations are met, the stock is fairly valued; if exceeded, it could be undervalued; if missed, it is significantly overvalued.
ECG is a compelling but risky investment at current levels. For growth investors willing to tolerate volatility, the 33% revenue growth and 32% ROE are attractive. However, with a forward PE of 32x and the stock up 156% in a year, much of the good news appears priced in. The lack of analyst consensus increases uncertainty. It could be a good buy on a pullback to the $130-$140 range where the growth story would offer better risk/reward. Conservative investors should wait for either a lower entry point or broader analyst coverage providing more price targets.
ECG is more suitable for medium to long-term investment (2-3 years) rather than short-term trading. While the stock exhibits high volatility that could attract traders, its investment thesis depends on sustaining multi-year growth trends to justify its valuation. The company pays no dividend, eliminating income appeal. Given its recent IPO status and ongoing narrative development, investors need time for the story to mature and analyst coverage to expand. A minimum holding period of 12-18 months is recommended to allow several earnings cycles to validate the growth trajectory.